Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial.

Date publication

octobre 2021

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier , Dr VERNEREY Dewi , Mme HENRIQUES Julie

Tous les auteurs :
Taieb J, Taly V, Henriques J, Bourreau C, Mineur L, Bennouna J, Desrame J, Louvet C, Lepere C, Mabro M, Egreteau J, Bouche O, Mulot C, Hormigos K, Chaba K, Mazard T, de Gramont A, Vernerey D, André T, Laurent-Puig P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34083233

Résumé

Circulating tumor DNA (ctDNA) has been suggested as a major prognostic factor in resected stage-III colon cancer. We analyzed ctDNA of patients randomized in the phase III IDEA-France trial.

Mots clés

Aged, Chemotherapy, Adjuvant, Circulating Tumor DNA, blood, Colonic Neoplasms, blood, Disease-Free Survival, Duration of Therapy, Female, Humans, Male, Neoplasm Staging, Prognosis, Prospective Studies

Référence

Clin Cancer Res. 2021 10 15;27(20):5638-5646